Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and Ipilimumab Post Stem Cell Transplant
NCT01919619Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2013
- Primary completion
- May 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide, ipilimumab in leukemia, lymphoma, multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2013; status: completed.
02
Drugs
lenalidomideipilimumab
03
Conditions
leukemialymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT01919619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01919619.